Tubulis

Executive Summary

Tubulis is a private biotechnology company focused on engineering next-generation antibody-drug conjugates (ADCs) for oncology. Founded in 2019 and headquartered in Cambridge, MA, the company has raised approximately $489 million to develop its proprietary TubuLINK™ platform, which enables the creation of highly stable and potent ADCs with improved therapeutic indices. This platform addresses key limitations of conventional ADCs, such as instability and off-target toxicity, by using a unique linker technology that ensures precise drug release within tumor cells. Tubulis aims to expand the treatment landscape for both solid tumors and hematological malignancies, with a preclinical pipeline targeting multiple validated cancer antigens. The company is currently advancing its lead ADC candidates toward clinical development. With strong financial backing from top-tier investors, Tubulis is well-positioned to submit its first Investigational New Drug (IND) application in the near term. Key upcoming milestones include the initiation of first-in-human trials for its lead program, TUB-001, targeting a solid tumor indication, as well as potential platform expansion through partnerships with larger biopharma companies. Given the promising preclinical data and the growing ADC market, Tubulis represents a compelling opportunity in the oncology space. However, as a preclinical entity, execution risk remains high, and near-term catalysts will be critical for validating its platform.

Upcoming Catalysts (preview)

• Q3 2026IND Filing for Lead ADC Candidate TUB-00160% success
• Q2 2026Presentation of Preclinical Data at Major Oncology Conference80% success
• Q4 2026Strategic Partnership or Licensing Deal for ADC Platform40% success